Larimar Therapeutics, Inc.

DB:ZA71 Stock Report

Market Cap: €244.9m

Larimar Therapeutics Valuation

Is ZA71 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZA71 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ZA71's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ZA71's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZA71?

Key metric: As ZA71 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ZA71. This is calculated by dividing ZA71's market cap by their current book value.
What is ZA71's PB Ratio?
PB Ratio1.3x
BookUS$198.40m
Market CapUS$254.91m

Price to Book Ratio vs Peers

How does ZA71's PB Ratio compare to its peers?

The above table shows the PB ratio for ZA71 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
HPHA Heidelberg Pharma
2.8x-33.0%€101.6m
2INV 2invest
1.1xn/a€67.3m
FYB Formycon
1.6x30.6%€927.0m
BIO3 Biotest
2x29.3%€1.3b
ZA71 Larimar Therapeutics
1.3x6.2%€254.9m

Price-To-Book vs Peers: ZA71 is good value based on its Price-To-Book Ratio (1.3x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does ZA71's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
ZA71 1.3xIndustry Avg. 2.3xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ZA71 is good value based on its Price-To-Book Ratio (1.3x) compared to the European Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is ZA71's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZA71 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ZA71's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ZA71 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.80
€19.68
+418.0%
34.9%€34.72€12.05n/a11
Dec ’25€6.20
€19.85
+220.2%
33.4%€33.98€11.67n/a11
Nov ’25€7.20
€19.10
+165.2%
35.8%€33.15€8.40n/a11
Oct ’25€5.70
€18.62
+226.7%
39.9%€32.68€8.28n/a8
Sep ’25€7.10
€20.46
+188.2%
38.8%€32.96€8.35n/a6
Aug ’25€7.60
€20.64
+171.6%
38.8%€33.24€8.42n/a6
Jul ’25€6.55
€20.64
+215.1%
38.8%€33.24€8.42n/a6
Jun ’25€6.40
€20.64
+222.5%
38.8%€33.24€8.42n/a6
May ’25€6.10
€18.34
+200.6%
40.5%€24.92€6.64n/a6
Apr ’25€6.60
€17.24
+161.2%
44.8%€24.71€6.58n/a5
Mar ’25€10.50
€15.16
+44.4%
46.0%€23.35€6.71n/a5
Feb ’25€5.30
€10.64
+100.8%
39.3%€15.68€4.15n/a5
Jan ’25€4.08
€10.85
+165.8%
37.7%€15.74€4.17n/a5
Dec ’24€3.08
€10.74
+248.6%
37.7%€15.59€4.13€6.205
Nov ’24€2.72
€10.87
+299.6%
37.7%€15.78€4.18€7.205
Oct ’24€4.04
€10.87
+169.1%
37.7%€15.78€4.18€5.705
Sep ’24€3.52
€10.74
+205.1%
37.7%€15.59€4.13€7.105
Aug ’24€3.84
€10.64
+177.1%
37.3%€15.38€4.07€7.605
Jul ’24€2.84
€10.55
+271.4%
34.9%€13.93€4.18€6.555
Jun ’24€3.42
€10.55
+208.4%
34.9%€13.93€4.18€6.405
May ’24€4.08
€10.60
+159.8%
26.2%€13.93€6.50€6.105
Apr ’24€3.72
€10.60
+185.0%
26.2%€13.93€6.50€6.605
Mar ’24€6.10
€9.92
+62.6%
36.6%€14.98€3.74€10.505
Feb ’24€4.44
€9.92
+123.3%
36.6%€14.98€3.74€5.305
Jan ’24€3.72
€9.92
+166.6%
36.6%€14.98€3.74€4.085
Dec ’23€2.96
€11.82
+299.3%
18.6%€15.45€9.65€3.084

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 09:47
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Larimar Therapeutics, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Samantha Lynn SemenkowCitigroup Inc
Samantha Lynn SemenkowCitigroup Inc